pfizer novo nordisk - Search News

Novo Nordisk Launches Bidding War With Pfizer

Novo Nordisk launches bidding war with Pfizer for US obesity biotech Metsera

Denmark's Novo Nordisk (NOVOb.CO) launched a rival bid for U.S. obesity biotech firm Metsera (MTSR.O) on Thursday, hijacking an offer from Pfizer (PFE.N) as the drugmakers jostled for advantage in the...

TipRanks on MSN · 8h

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

· 16h

Pfizer Faces Off With Novo Nordisk Over Metsera Bid

· 7h

Pfizer Sues to Stop Rival Bid for Drugmaker Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.

· 18h

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.

· 1d

Novo Nordisk hijacks Pfizer with bid for US biotech Metsera

· 1d

Novo Nordisk changes tack with bold raid on Pfizer obesity deal

"We asked them to become more aggressive and ambitious," said Mikael Bak, head of the Danish Shareholders' Association which has around 17,000 members, most of them investors in Novo.

· 1d

Metsera says Novo Nordisk’s $9B buyout offer “superior”; Pfizer calls bid “illusory”

STAT · 1d

Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer

6hon MSN

Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug Deal

Drugmaker Pfizer on Friday sued obesity-drug developer Metsera and Novo Nordisk, seeking to block Metsera from terminating its multibillion-dollar merger deal with Pfizer after Novo Nordisk made an unsolicited takeover bid.

Fierce Biotech

Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already announced plans to lay off about 9,000 employees worldwide and shutter the company’s cell therapy R&D work.